Biliverdin is the endogenous ligand of human serum α1-acid glycoprotein

Biochemical and Biophysical Research Communications

Volumn 372, Issue 3, 2008, Pages 503-507

  Zsila, Ferenc ^a   Mády, György ^a  

^a CHEMICAL RESEARCH CENTER   (Hungary)

Author keywords

Acute phase reaction; Biliverdin; Genetic variants; Human serum 1 acid glycoprotein; Induced circular dichroism; Lipocalin

Indexed keywords

BILIVERDIN; BILIVERDIN DIMETHYL ESTER; ESTER DERIVATIVE; LIGAND; OROSOMUCOID;

ARTICLE; BINDING AFFINITY; BINDING SITE; CIRCULAR DICHROISM; COMMERCIAL PHENOMENA; GENETIC VARIABILITY; PRIORITY JOURNAL; PROTEIN INTERACTION; ULTRAVIOLET SPECTROSCOPY;

BILIVERDINE; CHLORPROMAZINE; CIRCULAR DICHROISM; HUMANS; LIGANDS; MICROSCOPY, ULTRAVIOLET; MUTATION; OROSOMUCOID; PROTEIN STRUCTURE, SECONDARY;

EID: 44749084521     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.05.090     Document Type: Article

References (40)

1. Fournier T., Medjoubi N.N., and Porquet D. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta 1482 (2000) 157-171
2. Ceciliani F., and Pocacqua V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr. Protein Pept. Sci. 8 (2007) 91-108
3. Hochepied T., Berger F.G., Baumann H., and Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 14 (2003) 25-34
4. Tomei L., Eap C.B., Baumann P., and Dente L. Use of transgenic mice for the characterization of human alpha1-acid glycoprotein (orosomucoid) variants. Hum. Genet. 84 (1989) 89-91
5. Herve F., Caron G., Duche J.C., Gaillard P., Abd Rahman N., Tsantili-Kakoulidou A., Carrupt P.A., d'Athis P., Tillement J.P., and Testa B. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol. Pharmacol. 54 (1998) 129-138
6. Eap C.B., Fischer J.F., and Baumann P. Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions. Clin. Chim. Acta 203 (1991) 379-385
7. Breustedt D.A., Schonfeld D.L., and Skerra A. Comparative ligand-binding analysis of ten human lipocalins. Biochim. Biophys. Acta 1764 (2006) 161-173
8. Flower D.R., North A.C., and Sansom C.E. The lipocalin protein family: structural and sequence overview. Biochim. Biophys. Acta 1482 (2000) 9-24
9. Flower D.R. Experimentally determined lipocalin structures. Biochim. Biophys. Acta 1482 (2000) 46-56
10. Israili Z.H., and Dayton P.G. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33 (2001) 161-235
11. Colombo S., Buclin T., Decosterd L.A., Telenti A., Furrer H., Lee B.L., Biollaz J., and Eap C.B. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin. Pharmacol. Ther. 80 (2006) 307-318
12. Larghero J., Leguay T., Mourah S., Madelaine-Chambrin I., Taksin A.L., Raffoux E., Bastie J.N., Degos L., Berthaud P., Marolleau J.P., Calvo F., Chomienne C., Mahon F.X., and Rousselot P. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem. Pharmacol. 66 (2003) 1907-1913
13. Fuse E., Kuwabara T., Sparreboom A., Sausville E.A., and Figg W.D. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J. Clin. Pharmacol. 45 (2005) 394-403
14. Mestriner F.L., Spiller F., Laure H.J., Souto F.O., Tavares-Murta B.M., Rosa J.C., Basile-Filho A., Ferreira S.H., Greene L.J., and Cunha F.Q. Acute-phase protein alpha-1-acid glycoprotein mediates neutrophil migration failure in sepsis by a nitric oxide-dependent mechanism. Proc. Natl. Acad. Sci. USA 104 (2007) 19595-19600
15. Matsumoto K., Nishi K., Kikuchi M., Kadowaki D., Tokutomi Y., Tokutomi N., Nishi K., Suenaga A., and Otagiri M. Alpha1-acid glycoprotein suppresses rat acute inflammatory paw edema through the inhibition of neutrophils activation and prostaglandin E2 generation. Biol. Pharm. Bull. 30 (2007) 1226-1230
16. Osikov M.V., Makarov E.V., and Krivokhizhina L.V. Effects of alpha(1)-acid glycoprotein on hemostasis in experimental septic peritonitis. Bull. Exp. Biol. Med. 144 (2007) 178-180
17. de Vries B., Walter S.J., Wolfs T.G., Hochepied T., Rabina J., Heeringa P., Parkkinen J., Libert C., and Buurman W.A. Exogenous alpha-1-acid glycoprotein protects against renal ischemia-reperfusion injury by inhibition of inflammation and apoptosis. Transplantation 78 (2004) 1116-1124
18. Albani J.R. New insights in the conformation of alpha(1)-acid glycoprotein (orosomucoid). Quenching resolved emission anisotropy studies. Spectrochim. Acta A 55 (1999) 2353-2360
19. Sager G., Bratlid H., and Little C. Binding of catecholamines to alpha-1 acid glycoprotein, albumin and lipoproteins in human serum. Biochem. Pharmacol. 36 (1987) 3607-3612
20. Ojala P.J., Hermansson M., Tolvanen M., Polvinen K., Hirvonen T., Impola U., Jauhiainen M., Somerharju P., and Parkkinen J. Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry 45 (2006) 14021-14031
21. Albani J.R. Tertiary structure of human alpha1-acid glycoprotein (orosomucoid). Straightforward fluorescence experiments revealing the presence of a binding pocket. Carbohydr. Res. 339 (2004) 607-612
22. 1-acid glycoprotein. Biochim. Biophys. Acta 1760 (2006) 1704-1712
23. 1-Acid Glycoprotein, Kumamoto, Japan, 2000, pp. 45-54.
24. Zsila F., Bikádi Z., and Simonyi M. Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods. Biochem. Pharmacol. 65 (2003) 447-456
25. Hanada K., Tochikura N., and Ogata H. Selective binding of tamsulosin to genetic variants of human alpha1-acid glycoprotein. Biol. Pharm. Bull. 30 (2007) 1593-1595
26. 1-acid glycoprotein studied by circular dichroism spectroscopy. Biochem. Pharmacol. 67 (2004) 679-688
27. Boiadjiev S.E., and Lightner D.A. Optical activity and stereochemistry of linear oligopyrroles and bile pigments. Tetrahedron: Asymmetry 10 (1999) 607-655
28. Huber R., Schneider M., Mayr I., Muller R., Deutzmann R., Suter F., Zuber H., Falk H., and Kayser H. Molecular structure of the bilin binding protein (BBP) from Pieris brassicae after refinement at 2.0 Ǻ resolution. J. Mol. Biol. 198 (1987) 499-513
29. 1-acid glycoprotein: insight from induced circular dichroism and electronic absorption spectra. Biochim. Biophys. Acta 1770 (2007) 797-809
30. 1-acid glycoprotein genetic variants. Bioorg. Med. Chem. 14 (2006) 1959-1965
31. Nimberg R., Motoyama T., and Schmid K. The amino acid substitutions found in the genetic variants of alpah1-acid glycoprotein. J. Biol. Chem. 246 (1971) 5817-5821
32. 1-acid glycoprotein studied by circular dichroism and electronic absorption spectroscopy: the essential role of the conserved tryptophan residue. Biochim. Biophys. Acta 1760 (2006) 1248-1273
33. Herve F., Gomas E., Duche J.C., and Tillement J.P. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br. J. Clin. Pharmacol. 36 (1993) 241-249
34. Takahashi T., Shimizu H., Morimatsu H., Inoue K., Akagi R., Morita K., and Sassa S. Heme oxygenase-1: a fundamental guardian against oxidative tissue injuries in acute inflammation. Mini Rev. Med. Chem. 7 (2007) 745-753
35. Florczyk U.M., Jozkowicz A., and Dulak J. Biliverdin reductase: new features of an old enzyme and its potential therapeutic significance. Pharmacol. Rep. 60 (2008) 38-48
36. Overhaus M., Moore B.A., Barbato J.E., Behrendt F.F., Doering J.G., and Bauer A.J. Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators. Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006) G695-G703
37. Öllinger R., Wang H., Yamashita K., Wegiel B., Thomas M., Margreiter R., and Bach F.H. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid. Redox Signal. 9 (2007) 2175-2185
38. Bulmer A.C., Ried K., Blanchfield J.T., and Wagner K.H. The anti-mutagenic properties of bile pigments. Mutat. Res. 658 (2008) 28-41
39. Kirkby K.A., and Adin C.A. Products of heme oxygenase and their potential therapeutic applications. Am. J. Physiol. Renal. Physiol. 290 (2006) F563-F571
40. Abraham N.G., and Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev. 60 (2008) 79-127